Because Inside Every Cell Lies A Cure
We are a next-generation biotechnology company reimagining health span. At BICC, we blend ethical science, precision medicine, and regenerative technology into a bioecosystem that empowers humans to live longer, healthier lives. Our work spans patented therapies, novel supplement formulations, and scalable cell-based innovations.
The Global Aging Crisis:
A Looming Socioeconomic Challenge
The world is undergoing an unprecedented demographic shift as the global population aged 60 and above is projected to double to 2.1 billion by 2050, according to the World Health Organization. This "Silver Tsunami" presents profound challenges for societies and economies worldwide. Aging has emerged as the primary risk factor for degenerative conditions, with the Centers for Disease Control reporting that 80% of adults over 65 already suffer from at least one chronic disease...
Meet BICC
In 2024, BICC was founded by a visionary team of entrepreneurs, medical experts, and scientists united by a bold mission: to redefine aging through the fusion of cutting-edge stem cell science and consumer-focused wellness solutions. Backed by strategic investors, BICC made a transformative acquisition by taking over The Supplements Group (TSG), a move designed to integrate advanced biotechnology with scalable consumer health platforms.
Established in 2023, TSG leverages its agency-style sales force of over 3,000 representatives to drive strategic market engagement and growth. With a focus on stem cell-based nutritional supplements and innovative induced pluripotent stem cell (iPSC) banking services, TSG is poised to address one of the most pressing global challenges: aging populations and the rising prevalence of degenerative diseases. TSG’s mission is to become the world’s leading provider of science-backed health span solutions, combining biotechnology innovation with scalable distribution models. Leveraging blockchain technology for transparency and trust, TSG efficiently scales across diverse markets, including its established operations in Singapore, China, and Thailand, with planned expansions into Malaysia, Indonesia, and Vietnam end 2025.
​
With a clear pathway to a NASDAQ listing in 2026, BICC’s acquisition of TSG has not only accelerated international growth but has also solidified a cohesive platform that bridges groundbreaking science with global market reach.
​
Find out more about The Supplements Group (TSG) >
Our China Office:
Our Thailand Office:
The Science of Stem Cells
Stem cells are unique biological cells with the remarkable potential to develop into many different cell types in the body during early life and growth. They serve as a kind of internal repair system, dividing without limit to replenish other cells. Unlike regular cells, stem cells can either remain a stem cell or differentiate into specialized cells like muscle, brain, or blood cells.
ESC
Embryonic Stem Cells
Derived from early-stage embryos and are pluripotent, meaning they can become any cell type in the body.
ASC
Adult Stem Cells
Found in various tissues such as bone marrow and fat. They are multipotent and primarily maintain and repair their resident tissue.
IPSC
Induced Pluripotent Stem Cells
Adult cells reprogrammed to a pluripotent state, offering ethical alternatives to ESCs.
MSC
Mesenchymal Stem Cells
Found in bone marrow, adipose tissue, and umbilical cords, known for their anti-inflammatory, regenerative, and immunomodulatory properties.
Our Partners
Aetheris Labs
Wealth Index Capital Group
Beijing Tianyi Yuanfang Biotechnology
Shineco Inc. (NASDAQ: SISI)
Future FinTech Group (FTFT)
Biotech & Biomedicine (Shenyang) Group
Partner With Us!
We are supported by global biotech firms and emerging AI labs. Our listing partner and U.S.-based investors are helping us prepare for an international IPO.
Join us in shaping the future of health.